Transurethral laser ablation using 980-nm diode laser for recurrent non-muscle invasive bladder cancer

Abstract

Aim: Transurethral laser ablation (TULA) for recurrent bladder cancer is a less invasive treatment method for patients. We report here our initial clinical experience with TULA for recurrent bladder cancer.

Methods: This retrospective study analyzed 48 patients. Twenty-four cases were treated with TULA and another 24 cases were treated with transurethral resection of bladder tumor (TURBT) from Feb 2024 to Mar 2025 at Kochi Medical School Hospital. Intraoperative and postoperative outcomes and recurrence-free survival (RFS) were analyzed between TULA and TURBT.

Results: This study showed that TULA using a 980-nm diode laser was significantly shorter than TURBT in terms of perioperative results: operative time, hospital stay, catheterization, bladder irrigation, and postoperative hospital stay. Regarding the occurrence of complications, TULA was observed to be less prevalent than TURBT in all cases. Kaplan-Meier curves showed that TULA was significantly associated with longer RFS compared to TURBT (hazard ratio 4.739; 95% confidence interval, 1.272–17.65; p = 0.02039).

Conclusions: Our preliminary results showed that TULA for recurrent bladder cancer is feasible and safe.

Keywords

transurethral laser ablation / transurethral resection of bladder tumor / non-muscle invasive bladder cancer

References

[1] Sasaki T, Higashi T, Inoue T. Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan. Int J Clin Oncol. 2024; 29: 1088-95.

[2] Chopin DK, Gattegno B. Superficial bladder tumors. Eur Urol. 2002; 42: 533-41.

[3] Kobayashi T, Seki N, Song YH, Dejima T. GreenLight HPS laser 120 W vs diode laser 300 W vaporization of the prostate for the treatment of benign prostatic hyperplasia in Japanese patients: A prospective, single-center, randomized clinical trial. Low Urin Tract Symptoms. 2021; 13: 31-7.

[4] Furumido J, Ozaki N, Matsugase Y, Mori T. Evaluation of learning curves for contact laser vaporization of the prostate using the 980 nm diode laser for benign prostatic hyperplasia. Int J Urol. 2024; 31: 921-6.

[5] Yamamichi F, Inoue T, Fujita M, Tominaga K, Yamashita Y, Fujisawa M. Initial Experience of Contact Laser Vaporization of the Prostate Using the New Type of Fiber for Benign Prostatic Hyperplasia in a Single Institution. Low Urin Tract Symptoms. 2025; 17: e70002.

[6] Hermann GG, Mogensen K, Lindvold LR, Haak CS, Haedersdal M. Office-based transurethral devascularisation of low grade non-invasive urothelial cancer using diode laser. A feasibility study. Lasers Surg Med. 2015; 47: 620-5.

[7] Hermann GG, Mogensen K, Rosthøj S. Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation: efficacy, safety and economic analysis. Scand J Urol. 2018; 52: 194-8.

[8] Li C, Gao L, Zhang J, Yang X, Liu C. The effect of holmium laser resection versus standard transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Lasers Med Sci. 2020; 35: 1025-34.

[9] Razzaghi MR, Mazloomfard MM, Yavar M, Malekian S, Mousapour P. Holmium LASER in Comparison with Transurethral Resection of the Bladder Tumor for Non-muscle Invasive Bladder Cancer: Randomized Clinical Trial with 18-month Follow-up. Urol J. 2021; 18: 460-5.

[10] Wang W, Liu H, Xia S. Thulium laser treatment for bladder cancer. Asian J Urol. 2016; 3: 130- 3.

[11] Hashem A, Mosbah A, El-Tabey NA, Laymon M, Ibrahiem E, Elhamid MA, et al. Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle-invasive Bladder Cancer: A Randomized Clinical Trial. Eur Urol Focus. 2021; 7: 1035-43.

[12] Yao Z, Li Y, Ding Y, Hou Y, Hu J, Liu Z, et al. Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters ≥3cm compared to transurethral resection: a non-randomized controlled study. BMC Cancer. 2024; 24: 1239.

[13] Beer M, Jocham D, Beer A, Staehler G. Adjuvant laser treatment of bladder cancer: 8 years’ experience with the Nd-YAG laser 1064 nm. Br J Urol. 1989; 63: 476-8.

[14] Pierre SA, Albala DM. The future of lasers in urology. World J Urol. 2007; 25: 275-83.

[15] Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS, et al. 980-nm Diode laser: a novel laser technology for vaporization of the prostate. Eur Urol. 2007; 52: 1723-8.

[16] Mao T, Zhang H, Cui J, Zhao Z, Jiao D, Zhang W. The 980 nm diode laser treatment for non-muscle-invasive bladder tumor with en bloc technique: single-center experience. World J Surg Oncol. 2022; 20: 324.

[17] Non-muscle-invasive Bladder Cancer [Internet]. [cited 2026 Jun 1]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/disease-management

[18] Pedersen GL, Erikson MS, Mogensen K, Rosthøj S, Hermann GG. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol. 2023; 83: 125-30.